The review comes amid growing attention directed at identifying treatments that can prevent progression of polycythemia vera (PV) to myelofibrosis or an aggressive form of acute myeloid leukemia.
A pair of researchers outlined the most recent developments in prognostic markers and treatment advances in polycythemia vera (PV), including pegylated interferon-alpha 2 (IFN-alfa-2a), mouse double-minute homolog 2 (MDM2) antagonists, hepcidin mimetics, and histone deacetylase inhibitors.
The review comes amid growing attention directed at identifying treatments that can prevent progression of PV to myelofibrosis or an aggressive form of acute myeloid leukemia.
“Ultimately, the goals of therapy in this chronic disease are to improve quality of life, reduce risk of thrombosis, and alter disease course,” wrote the pair. “The therapeutic landscape of PV is evolving because of a more thorough understanding of the molecular mechanisms driving the pathogenesis and progression of this disease.”
For example, some focus has been paid to combining pegylated interferon (IFN) with agents like ruxolitinib. A phase 2 study looking at the treatment combination in 32 patients with PV and myelofibrosis showed a 31% remission rate and 9% complete remission rate. Notably, the study also showed that a significant number of patients cannot tolerate IFN-alfa-2a, with nearly one-third of patients in the study dropping out, likely due to the side effects of the treatment.
Another phase 2 randomized study is currently assessing the effects of ropeginterferon-alfa-2b compared with phlebotomy alone in patients with low-risk PV. Interim results indicated that 84% of patients receiving the IFN-alfa-2a treatment met the primary endpoint of percentage of patients maintaining a hematocrit of not more than 45% over 1 year without evidence of disease progression (P = .008). In comparison, 60% of patients receiving phlebotomy alone met the endpoint.
MDM2 inhibitors have also been suggested as an attractive treatment class. A phase 1 study of patients with refractory PV receiving oral MDM2 antagonist idasanutlin showed a 58% response rate and a 50% response rate when the treatment was combined with IFN-alfa-2a treatment.
Results from a phase 2 study of the nutlin KRT-232 are anticipated. The study includes phlebotomy-dependent patients with PV.
With iron deficiency being a prevalent issue among patients with PV, the addition of hepcidin agonists is being explored to restrict systemic iron metabolism. PTG-300 is currently being studied in a phase 2 trial of 13 patients with PV, with preliminary findings indicating that the treatment is both safe and tolerable. All patients have maintained hematocrit of less than 45% without phlebotomy for up to 7 months, and iron deficiency appears to be reversing based on increasing ferritin, iron, and transferrin saturation levels.
A fourth class of treatment, histone deacetylase inhibitors, is also being explored. Givinostat was tested in a phase 1b/2 study of patients with PV, which established the maximum tolerated dose of the treatment to be 100 mg twice a day. Study results also showed a high response rate.
“Further study is needed to determine whether these agents have a role in reducing thrombosis risk and preventing disease progression to myelofibrosis and myeloproliferative neoplasms blast phase,” researchers said.
“Given that PV is a chronic disease, it is essential that these therapeutics be safe and tolerable to allow for prolonged treatment. The future of PV treatment likely will require combination treatments, which are being explored in preclinical studies," they concluded.
Reference: Marcellino BK and Hoffman R. Recent advances in prognostication and treatment of polycythemia vera. Fac Rev. Published online March 12, 2021. doi: 10.12703/r/10-29
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More